Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra.
Royo-Cebrecos C, Vilanova D, López J, Arroyo V, Pons M, Francisco G, Carrasco MG, Piqué JM, Sanz S, Dobaño C, García-Basteiro AL. Royo-Cebrecos C, et al. Among authors: arroyo v. Lancet Reg Health Eur. 2021 May 21;5:100119. doi: 10.1016/j.lanepe.2021.100119. eCollection 2021 Jun. Lancet Reg Health Eur. 2021. PMID: 34557824 Free PMC article.
Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
Feio-Azevedo R, Boesch M, Radenkovic S, van Melkebeke L, Smets L, Wallays M, Boeckx B, Philips G, Prata de Oliveira J, Ghorbani M, Laleman W, Meersseman P, Wilmer A, Cassiman D, van Malenstein H, Triantafyllou E, Sánchez C, Aguilar F, Nevens F, Verbeek J, Moreau R, Arroyo V, Denadai Souza A, Clària J, Lambrechts D, Ghesquière B, Korf H, van der Merwe S. Feio-Azevedo R, et al. Among authors: arroyo v. Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000907. Online ahead of print. Hepatology. 2024. PMID: 38761406
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.
Liu J, MacNaughtan J, Kerbert AJC, Portlock T, Martínez Gonzalez J, Jin Y, Clasen F, Habtesion A, Ji H, Jin Q, Phillips A, De Chiara F, Ingavle G, Jimenez C, Zaccherini G, Husi K, Rodriguez Gandia MA, Cordero P, Soeda J, McConaghy L, Oben J, Church K, Li JV, Wu H, Jalan A, Gines P, Solà E, Eaton S, Morgan C, Kowalski M, Green D, Gander A, Edwards LA, Cox IJ, Cortez-Pinto H, Avery T, Wiest R, Durand F, Caraceni P, Elosua R, Vila J, Pavesi M, Arroyo V, Davies N, Mookerjee RP, Vargas V, Sandeman S, Mehta G, Shoaie S, Marchesi J, Albillos A, Andreola F, Jalan R. Liu J, et al. Among authors: arroyo v. Gut. 2024 Apr 25:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699. Online ahead of print. Gut. 2024. PMID: 38621924
Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis.
Mücke MM, Hernández-Tejero M, Gu W, Kuhn M, Janz M, Keller MI, Fullam A, Altepeter L, Mücke VT, Finkelmeier F, Schwarzkopf KM, Cremonese C, Hunyady PM, Heilani MW, Uschner FE, Schierwagen R, Brol MJ, Fischer J, Klein S, Peiffer KH, Hogardt M, Shoaie S, Coenraad MJ, Bojunga J, Arroyo V, Zeuzem S, Kempf VAJ, Welsch C, Laleman W, Bork P, Fernandez J, Trebicka J; MICROB-PREDICT and PREDICT Study Group of the EASL-CLIF Consortium. Mücke MM, et al. Among authors: arroyo v. Aliment Pharmacol Ther. 2024 Apr;59(7):877-888. doi: 10.1111/apt.17899. Epub 2024 Feb 27. Aliment Pharmacol Ther. 2024. PMID: 38414095
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.
Torp N, Israelsen M, Coenraad M, Papp M, Shawcross D, Korenjak M, Angeli P, Laleman W, Juanola A, Gines P, Trebicka J, Krag A; MICROB-PREDICT Consortium. Torp N, et al. BMJ Open. 2024 Feb 14;14(2):e079309. doi: 10.1136/bmjopen-2023-079309. BMJ Open. 2024. PMID: 38355195 Free PMC article. Clinical Trial.
560 results